BioXcel Therapeutics
BTAI
85 hedge funds and large institutions have $140M invested in BioXcel Therapeutics in 2022 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 32 increasing their positions, 28 reducing their positions, and 15 closing their positions.
174% more call options, than puts
Call options by funds: $2.56M | Put options by funds: $933K
14% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 28
0.19% less ownership
Funds ownership: 2.83% → 2.65% (-0.19%)
10% less funds holding
Funds holding: 94 → 85 (-9)
16% less capital invested
Capital invested by funds: $167M → $140M (-$27.2M)
53% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Nuveen
Charlotte,
North Carolina
|
+$1.54M |
| 2 |
BlackRock
New York
|
+$581K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$503K |
| 4 |
Massachusetts Financial Services
Boston,
Massachusetts
|
+$448K |
| 5 |
Morgan Stanley
New York
|
+$405K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$5.17M |
| 2 |
Millennium Management
New York
|
-$2.49M |
| 3 |
Two Sigma Investments
New York
|
-$1.22M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$1.2M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$1.17M |
BTAI Hedge Fund Activity: Q3 2022 in Review
85 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in BioXcel Therapeutics (BTAI) for Q3 2022, worth a combined $140M — down 16% from $167M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of BTAI and 7 opened new positions — a net loss of 8 holders — while 28 trimmed existing stakes and 32 added.
The largest buyer was Nuveen, adding an estimated $1.54M. The largest seller was Rubric Capital Management (New York), exiting entirely with an estimated $5.17M sold.
- 85 institutional investors held BioXcel Therapeutics (BTAI) as of Q3 2022, down from 94 in Q2 2022.
- Funds reported $140M of BioXcel Therapeutics stock for Q3 2022, down 16% quarter-over-quarter.
- 7 funds opened new BioXcel Therapeutics positions in Q3 2022 and 15 closed out, a net change of -8 holders.
- The largest BioXcel Therapeutics buyer in Q3 2022 was Nuveen, an estimated $1.54M added.
- The largest BioXcel Therapeutics seller in Q3 2022 was Rubric Capital Management (New York), an estimated $5.17M sold.
Based on aggregated 13F filings for Q3 2022.